Ned is a lead editor for BioPharma Dive. Before joining Industry Dive, Ned covered economic news for a Japanese newswire and contributed articles on political risk for Global Risk Insights. He has a B.A. from the College at Georgetown University.
1927 articles by Ned Pagliarulo
-
Caribou raises $304M in one of gene editing's most lucrative IPOs
July 23, 2021 -
Biogen executives attack Aduhelm criticism, blaming 'extensive misinformation'
July 22, 2021 -
J&J predicts faster coronavirus vaccine sales amid debate over boosters
July 21, 2021 -
Amylyx, faced with longer FDA path for promising ALS drug, gets major cash infusion
July 20, 2021 -
Cytokinetics heart drug succeeds in mid-stage study, boosting shares
July 19, 2021 -
Questions on new Alzheimer's drug benefit, price loom large at ICER meeting
July 16, 2021 -
Galapagos shares sink as first data from touted drug program disappoints
July 15, 2021 -
Medicare to weigh nationwide coverage rules for Biogen Alzheimer's drug
July 12, 2021 -
Novo, in rare deal, buys rights to Prothena amyloidosis treatment
July 12, 2021 -
FDA, under fire for Alzheimer's drug approval, seeks investigation of review process
July 9, 2021 -
Biohaven beats expectations with fast sales of migraine drug
July 8, 2021 -
FDA revises labeling of Biogen's Alzheimer's drug to emphasize early treatment
July 8, 2021 -
A well-funded cancer drug startup brings on GSK's Axel Hoos as CEO
July 7, 2021 -
Moderna puts seasonal flu vaccine ambitions to the test
July 7, 2021 -
Lilly, Boehringer say diabetes drug first to succeed in hard-to-treat heart failure
July 6, 2021 -
5 FDA decisions to watch in the third quarter
July 2, 2021 -
CureVac vows to seek vaccine approval despite low efficacy in COVID-19 study
July 1, 2021 -
Beam, Apellis partner in deal to expand gene editing's reach
June 30, 2021 -
ICER stands by view on Biogen's Aduhelm, says sharp price cut needed
June 30, 2021 -
Gilead, Foresite back biotech developer of COVID-19 pill in latest SPAC deal
June 29, 2021 -
Gilead matches Bristol Myers in showing benefit to earlier CAR-T treatment
June 28, 2021 -
FDA advisers vote down Incyte cancer drug as agency takes tougher line
June 25, 2021 -
Reversing course, Lilly to seek fast approval for experimental Alzheimer's drug
June 24, 2021 -
Third Rock-backed startup launches to develop cell therapies for MS, diabetes
June 23, 2021 -
FDA documents show how controversial Alzheimer's drug decision was reached
June 22, 2021